Ran Yan

Ran Yan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
RYRan Yan
Ran Yan
LALesley Andrew
Lesley Andrew
EMEvania Marlow
Evania Marlow
KKKanita Kunaratnam
Kanita Kunaratnam
ADAmanda Devine
Amanda Devine
CCClaus Christophersen
Claus Christophersen
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting 4–5% of the global population. This disorder is associated with gut microbiota, diet, sleep, and mental health. This scoping review therefore aims to map existing research that has administrated fibre-related dietary intervention to IBS individuals and reported outcomes on at least two of the three following themes: gut microbiota, sleep, and mental health. Five digital databases were searched to identify and select papers as per the inclusion and exclusion criteria. Five articles were included in the assessment, where none reported on all three themes or the combination of gut microbiota and sleep. Two studies identified alterations in gut microbiota and mental health with fibre supplementation. The other three studies reported on mental health and sleep outcomes using subjective questionnaires. IBS-related research lacks system biology-type studies targeting gut microbiota, sleep, and mental health in patients undergoing diet intervention. Further IBS research is required to explore how human gut microbiota functions (such as short-chain fatty acids) in sleep and mental health, following the implementation of dietary pattern alteration or component supplementation. Additionally, the application of objective sleep assessments is required in order to detect sleep change with more accuracy and less bias.

17 August 2020 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
RYRan Yan
Ran Yan
MMMandy Murphy
Mandy Murphy
AGAngela Genoni
Angela Genoni
EMEvania Marlow
Evania Marlow
IDIan Charles Dunican
Ian Charles Dunican
CCClaus Christophersen
Claus Christophersen
Introduction A diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is an effective way to reduce gut symptoms in people with irritable bowel syndrome (IBS). This diet reduces the intake of fermentable fibres, leading to changes of the gut microbiota and insufficient fermentation in the large bowel, resulting in reduced production of short-chain fatty acids (SCFAs), such as butyrate, which has unfavourable implications for gut health, sleep and mental health. This study will examine the effect of Fibre-fix, a supplement containing a mix of dietary fibres, on the human gut microbiome composition, fermentative capacity, sleep, quality of life (QOL) and mental health of people with IBS who consume a low FODMAP diet (LFD). Methods and analysis A randomised, double-blind, placebo-controlled, study design is proposed to examine whether Fibre-fix added to an existing LFD may help modulate gastrointestinal function, improve markers of sleep, mental health and promote QOL in patients with IBS. Participants will provide stool and blood samples, daily bowel symptoms diaries and 3-day diet records. Additionally, they will complete validated questionnaires relating to FODMAP intake, sleep, mental health and QOL before and after a 3-week intervention. Gut health will be assessed via faecal microbiome composition, faecal pH and SCFA levels. Alteration of sleep will be recorded using an actigraphy device worn by all participants over the whole study. Multivariate analysis will be used to examine the gut microbiome and repeated measures Analysis of variance (ANOVA) will be used for dependent variables from questionnaires related to bowel symptoms, stool type, sleep, mental health and QOL to assess the differences between intervention and control groups after adjustment for confounding variables. Ethics and dissemination Ethics approval was obtained from the Human Research Ethics Committee of Edith Cowan University (2019-00619-YAN). Results will be disseminated in peer-review journal publications, and conference presentations. Participants will be provided with a summary of findings once the study is completed. If Fibre-fix is shown to result in favourable changes in gut microbial composition, SCFA production, sleep and mental well-being without exacerbating symptoms, this will provide additional dietary management options for those with IBS following an LFD. Trial registration number ACTRN12620000032954.

24 September 2026 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
RYRan Yan
Ran Yan
ADAmanda Devine
Amanda Devine
JLJohnny Lo
Johnny Lo
EMEvania Marlow
Evania Marlow
IDIan C. Dunican
Ian C. Dunican
CCClaus T. Christophersen
Claus T. Christophersen
Purpose: A diet low in FODMAP may negatively affect the gut microbiota of some Irritable Bowel Syndrome (IBS) patients, despite alleviating symptoms. This pilot study comprehensively explores the effects of a 3-week ur gut ® supplementation on gut microbiota, gut health, dietary intake, sleep, mental health and quality of life (QOL) in individuals with IBS following a low FODMAP diet. Methods: Adult participants ( n = 26, 3 males) completed a randomised, double-blind controlled study. Participants were provided with either ur gut ® ( n = 13) or placebo ( n = 13) for 3 weeks after a 1-week baseline. At baseline and end of intervention, blood, 24-h faecal samples and 3-day weighed-food diaries were collected. Validated questionnaires were used to evaluate mental health, sleep, QOL and gut symptoms. Participants reported daily IBS symptoms and wore a wrist-based actigraphy to capture daily sleep. Results: During the intervention, both groups maintained baseline stable gut symptoms and sleep patterns. After the intervention, the ur gut ® group had lower energy ( P < 0.05) and protein ( P < 0.01) intake compared to the placebo group, and increased resistant starch intake ( P < 0.001) compared to baseline. Changes in overall genus-level gut microbiota composition ( P < 0.01), including Ruminococcus E (5.5-fold increase, P < 0.01), were observed. ur gut ® improved GI-specific anxiety ( P = 0.01) and sexual subscale of QOL ( P < 0.05). Conclusion: Compared with placebo, ur gut ® increased dietary fibre intake, improved gut microbiota and gastrointestinal-specific anxiety without negatively impacting sleep, despite no changes observed in faecal and blood biomarkers. This provides a dietary strategy to support gut health without compromising symptom control in IBS. Australia and New Zealand Clinical Trial Registry http://www.anzctr.org.au/ , ACTRN12620000032954.

1 April 2019 in Journal of Oral & Facial Pain and Headache
Verified
Journal Article
Closed access
RYRan Yan
Ran Yan
XWXin Wang
Xin Wang
HZHaiBo Zhou
HaiBo Zhou
XLXin Li
Xin Li
YDYanBo Diao
YanBo Diao
YZYashuang Zhao
Yashuang Zhao
Aims: To evaluate the efficacy of sucrose in the prevention of migraine attacks. Methods: Two randomized double-blinded pilot trials were conducted, one in college students and one in adults. Migraineurs were randomized into two groups that each received an oral liquid: for students, sucrose 5 g/day (s-group; n = 12) or glucose 2.5 g/day (g-group; n = 10) for 3 months; and for adults, sucrose 5 g/day (s-group; n = 10) or fructose 2.5 g/day (f-group; n = 9) for 6 months. The primary endpoint was the frequency of migraine attacks per month, and the secondary endpoints were mean duration and severity of migraine per attack. Continuous measurements were described as mean +/- standard deviation (SD). The overall significance of the effects between different groups was tested using repeated measures analysis of variance (RANOVA), and the efficacy was evaluated using an intent-to-treat analysis. Results: Migraine frequency in the students declined significantly in the g-group (mean reduction +/- SD: 0.65 +/- 0.71; P < .01), but not in the s-group (0.33 +/- 2.02; P = .58). RANOVA results suggested that the secondary endpoints significantly declined over time (all P < .01) with no differences between the groups. In the adult trial, mixed-effects model analysis showed that both the primary and secondary endpoints significantly declined over time with no significant differences between the groups. Conclusion: Long-term consumption of a 5-g dose of sucrose for adult migraineurs or a 2.5-g dose of glucose for college student migraineurs may be as effective as preventive treatments.